Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Choose from a selection of modern and traditional designs in single or twin packs to support type 1 diabetes research this Christmas. Shop online and get fast delivery.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Professor Colin Dayan presented with the 2023 JDRF Rumbough Award
The JDRF David Rumbough Award acknowledges an individual who has made outstanding contributions in the field of type 1 diabetes that have significantly accelerated our mission.
For over 20 years, Professor Dayan has been a leader in type 1 immunotherapy research, and his work has been central to our research strategy and overall mission. He is leading efforts to bring teplizumab, the first disease-modifying therapy approved by the US Food and Drug Administration to Europe and the UK, which would expand treatment options.
He is a leading member of the JDRF-funded UK Type 1 Diabetes Research Consortium, through which he has brought the research community together to accelerate critical research, leverage collective resources, and collaborate to improve type 1 clinical trial delivery.
Currently, Professor Dayan serves as chair of Clinical Diabetes and Metabolism and head of section at Cardiff University School of Medicine and as part-time senior clinical researcher in the Nuffield Department of Medicine at the University of Oxford.
JDRF Chief Scientific Officer Sanjoy Dutta, Ph.D says: “Professor Dayan has played a significant role in advancing disease-modifying therapies for type 1 diabetes that will continue to have a profound impact on the global type 1 research community and those who are affected by the condition. JDRF is proud to honour Professor Dayan for his indelible contributions and work that supports and furthers our mission.”
Donate to JDRF today so that we can continue funding amazing research to develop cures and treatments for type 1 diabetes.
These are the takeaways that matter most to our community from EASD, Europe’s biggest diabetes conference.
INNODIA has announced positive results from its clinical trial MELD-ATG at the EASD conference in Vienna this year.
We’re pleased to announce that we are launching a new initiative to raise awareness of the importance of early detection in type 1 diabetes (T1D), with support from Sanofi.
In a landmark moment, the MHRA has licensed the use of teplizumab in the UK, the first-ever disease-modifying therapy for T1D.
